Clinical Trial

Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to find the highest tolerable dose of JV-394 (a type of autologous CAR-T cell therapy) that can be given to patients who have T/NK cell lymphoma that is relapsed or refractory. The safety and possible side effects of JV-394 will also be studied.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2026-01-30; most recent amendment 2026-07-14.
Status change: Not Yet Recruiting → Recruiting 2026-02-20
Trial Details
NCT Number NCT07382817
Lead Sponsor M.D. Anderson Cancer Center
Conditions Neoplasms
Enrollment 33 participants
Start Date 2026-02-18
Primary Completion 2029-12-09 (estimated)
Study Completion 2031-12-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-12